Covington & Burling LLP advises Novartis AG on its $12 billion acquisition of Avidity Biosciences Inc., represented by Kirkland & Ellis LLP, including the spin-off of Avidity's early-stage cardiology programs into SpinCo.
Avidity Biosciences, Inc. sold the stake/assets to Novartis AG as part of a acquisition on not available.
Deal value was 12000000000 (source: Extracted) Sector: Biopharmaceuticals; Location: USA.
On the seller side, not available advised, led by Graham Robinson, Laura Knoll, Greg Schuster, Merric Kaufman, Imran Malek, Bri Langa, Zohra Yaqhubi, Lara Pillay, Amy Tong, Audrey Lee, Jen Lee, Tamar Donikyan, Christina Thomas, Dennis Williams, Will Richmond, Robert Kantrowitz, Shellie Freedman, David MacDonald, Rami Sherman, Stefan Atkinson, Jace Cearley, Daniel Lim, Justin Coddington, Timothy Nelson, Stephanie Jeane, Ian John, Stephen Mohr, Rebekah Scherr, John Kabealo, Roberto Miceli, Dean Shulman, Liam Murphy.
Generated by AI, original source from - Data is in progress
Found it useful? Spread the word.
Covington & Burling LLP advises Novartis AG on its $12 billion acquisition of Avidity Biosciences Inc., represented by Kirkland & Ellis LLP, including the spin-off of Avidity's early-stage cardiology programs into SpinCo. | The Sponsor - The Sponsor
